Nevertheless, the alarming levels of spread and severity have forced the pharma/biotech companies to evaluate some approved drugs and determine if they are effective in treating infected patients.Incyte INCY also initiated RUXCOVID, a global, randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of Jakafi plus SoC in patients 12 years and above with COVID-19-associated cytokine storm.